Robert Yauch

Robert Yauch

Company: Genentech

Job title: Director & Principal Scientist, Discovery Oncology


Robert Yauch is the Director of Discovery Oncology at Genentech.  His group is focused on the discovery and validation of novel oncology drug targets in the areas of epigenetics, transcriptional control, cell cycle, DNA damage response and drug resistance.  He additionally oversees functional genomic and pharmaco-genomic efforts to support oncology projects within Genentech.  He has more than 20 years of experience in the biotech and pharmaceutical industry, highlighted by a key contribution to the discovery and development of the FDA-approved drug, vismodegib.  Robert has contributed over 50 peer-reviewed manuscripts and holds issued US patents.

Robert holds a Ph.D. in Immunology from Northwestern University and was a fellow at the Dana Farber Cancer Institute, Harvard Medical School.



Targeting SMARCA4-mutant lung cancers through selective, chemically-induced degradation of SMARCA2 3:45 pm

SMARCA4 is mutationally-inactivated in subsets of lung cancer leading to a dependency on the paralog helicase, SMARCA2 The discovery and development of selective SMARCA2 inhibitors would be essential for therapeutically targeting SMARCA4-mutant lung cancers In vitro characterization and demonstration of in vivo activity of potent and selective degraders of SMARCA2Read more

day: Virtual Conference Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.